Investigational daily pill doubles survival in metastatic pancreatic cancer, study shows
June 01, 2026
June 01, 2026
LOS ANGELES, California, June 1 -- The University of California posted the following news release:
* * *
Investigational daily pill doubles survival in metastatic pancreatic cancer, study shows
*
Key takeaways
* A study co-led by UCLA found patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median of 13.2 months compared with . . .
* * *
Investigational daily pill doubles survival in metastatic pancreatic cancer, study shows
*
Key takeaways
* A study co-led by UCLA found patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median of 13.2 months compared with . . .